(Q40495612)

21 September 2017

1 reference

title

Teicoplanin: 10 years of clinical experience (English)

1 reference

21 September 2017

M Trautmann

1

1 reference

21 September 2017

H Wiedeck

2

1 reference

21 September 2017

M Ruhnke

3

1 reference

21 September 2017

M Oethinger

4

1 reference

21 September 2017

R Marre

5

1 reference

21 September 2017

1 November 1994

1 reference

21 September 2017

1 reference

21 September 2017

22

1 reference

21 September 2017

6

1 reference

21 September 2017

430-436

1 reference

https://scigraph.springernature.com/pub.10.1007/bf01715507

21 September 2017

0 references

cites work

In vitro activity and human pharmacokinetics of teicoplanin

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

4-week treatment of streptococcal native valve endocarditis with high-dose teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Comparative in vitro activities of teicoplanin, vancomycin, oxacillin, and other antimicrobial agents against bacteremic isolates of gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin, and PD127,391 against blood isolates of gram-positive cocci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Resistance to vancomycin and teicoplanin: an emerging clinical problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Comparison of vancomycin- and teicoplanin-induced histamine release and "red man syndrome".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

A multicentre open clinical trial of teicoplanin in infections caused by gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Clinical evaluation of teicoplanin for therapy of severe infections caused by gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Efficacy of teicoplanin for enterococcal infections: 63 cases and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Emergence of teicoplanin resistance during therapy of Staphylococcus aureus endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Teicoplanin in the treatment of gram-positive-bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Intraperitoneal teicoplanin in the treatment of peritonitis associated with continuous ambulatory peritoneal dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

A review of the safety profile of teicoplanin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF01715507

Comparison of efficacy and safety of teicoplanin in gram-positive infections: a multicentre study

21 January 2018

1 reference

12 December 2020

Dosage recommendations for teicoplanin

1 reference

12 December 2020

Coagulase-negative staphylococcal bacteraemia treated with teicoplanin

1 reference

12 December 2020

A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer

1 reference

12 December 2020

Teicoplanin in the treatment of skin and soft tissue infections

1 reference

12 December 2020

Mild nephrotoxicity associated with vancomycin use.

1 reference

12 December 2020

In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococi, enterococci and Clostridium difficile

1 reference

12 December 2020

Teicoplanin, its pharmacokinetics, blister and peritoneal fluid penetration

1 reference

12 December 2020

Options and limitations of teicoplanin in febrile granulocytopenic patients

1 reference

12 December 2020

Teicoplanin monotherapy of serious infections caused by Gram-positive bacteria: a re-evaluation of patients with endocarditis or Staphylococcus aureus bacteraemia from a European open trial

1 reference

12 December 2020

The use of a new glycopeptide antibiotic, teicoplanin, in the treatment of bacterial endocarditis

1 reference

12 December 2020

Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients

1 reference

12 December 2020

Teicoplanin, a new antibiotic effective against gram-positive bacterial infections of the skin and soft tissues

1 reference

12 December 2020

Use of teicoplanin for Hickman catheter associated staphylococcal infection in immunosuppressed patients.

1 reference

12 December 2020

Clinical efficacy and safety of teicoplanin

1 reference

12 December 2020

Pharmacokinetics of teicoplanin in man after intravenous administration

1 reference

12 December 2020

Teicoplanin: Part 2. Evaluation of its use in the biliary system

1 reference

12 December 2020

The pharmacokinetics and tissue penetration of teicoplanin

1 reference

12 December 2020

Intravenous or Intramuscular Teicoplanin Once Daily for Skin and Soft-Tissue Infections

1 reference

12 December 2020

Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. The Swedish CDAD Study Group

1 reference

12 December 2020

Teicoplanin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential

1 reference

12 December 2020

Susceptibility of Clostridium difficile strains to new antibiotics: quinolones, efrotomycin, teicoplanin and imipenem

1 reference

12 December 2020

Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. II. Extraction and chemical characterization

1 reference

12 December 2020

An outbreak of group A streptococcal skin infection: control by source isolation and teicoplanin therapy

1 reference

12 December 2020

Microbiological properties of teicoplanin

1 reference

12 December 2020

Teicoplanin revisited

1 reference

12 December 2020

Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium

1 reference

12 December 2020

Relationship of serum antibiotic concentrations to nephrotoxicity in cancer patients receiving concurrent aminoglycoside and vancomycin therapy.

1 reference

12 December 2020

Clinical evaluation of teicoplanin in the treatment of gram-positive bacterial intravascular infections

1 reference

12 December 2020

Therapy of serious gram-positive infections with teicoplanin

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01715507

1 reference

21 September 2017

1 reference